Denmark's Novo Nordisk has agreed to pay $70 million to license rights to a drug developed by Ventus Therapeutics with ... stage candidates partnered with Dicerna and UBE. Novo Nordisk follows ...
That includes Moderna itself, which is working on rare disease candidates, as well as Axcella Therapeutics ... takeover of gene-silencing specialist Dicerna Pharma last year, another deal aimed ...
After hours: February 7 at 5:11:42 PM EST Loading Chart for IPSC ...
Dyne Therapeutics Inc.-5.60% $1.56B ...
After hours: February 7 at 5:14:26 PM EST Loading Chart for HRTX ...
Sanofi S.A. Part Cert 0.02% €8.03M ...
DiveWire guarantees visibility for your news announcements through instant distribution to BioPharma Dive’s audience and its 176,000 newsletter subscribers for 21 days.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback